^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | RMC-9805 (KRAS G12D inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
526 / 26 - RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Published date:
03/15/2023
Excerpt:
In a mouse clinical trial with KRAS G12D xenograft tumor models, RMC-9805 administered orally as a single agent was well tolerated and induced objective responses in 7 of 9 PDAC PDX and CDX models and 6 of 9 NSCLC PDX models, as assessed by mRECIST.
